CLAIMS:

1. Use of at least one serotonergic compound selected from the group comprising serotonin 5HT2A receptor antagonists, serotonin 5HT1A receptor antagonists selective serotonin uptake inhibitors (SSRIs) and serotonin antagonist and reuptake inhibitors (SARIs), or pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for treating flavivirus-induced thrombocytopenia.

2. The use of claim 1, wherein the at least one serotonergic compound, or pharmaceutically acceptable salt or solvate thereof, inhibits serotonin release and/or inhibits serotonin activity.

3. The use of claim 1 or 2, wherein the medicament comprises at least one serotonin 5HT2A receptor antagonist and/or at least one serotonin 5HT1A receptor antagonist.

4. The use of any one of the previous claims, wherein the at least one serotonergic compound is selected from the group comprising:
5HT2A receptor inhibitors such as
ketanserin [3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione],
sarpogrelate [4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid],
ritanserin [6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one],
fananserin [2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide];
5HT1A receptor inhibitors such as
WAY 100135 [(S)-N-tert-butyl- 3-(4-(2-methoxyphenyl)- piperazin-1-yl)- 2-phenylpropanamide],
methiothepin [1-methyl-4-(3-methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazine],
pindolol [1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol],
dotarizine [1-(Diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine] and
flopropione [1-(2,4,6-Trihydroxyphenyl)-1-propanone];
selective serotonin uptake inhibitors (SSRIs) or serotonin antagonist and reuptake inhibitors (SARIs) such as fluoxetine, paroxetine, citalopram, etoperidone and lorpiprazole,
or pharmaceutically acceptable salt or solvate thereof.

5. The use of claim 4, wherein the at least one serotonergic compound is selected from the group comprising:
ketanserin [3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione],
sarpogrelate [4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid] and
WAY 100135 [(S)-N-tert-butyl- 3-(4-(2-methoxyphenyl)- piperazin-1-yl)- 2-phenylpropanamide], or pharmaceutically acceptable salt or solvate thereof.

6. The use of any one of the previous claims, wherein the virus is selected from the group comprising dengue virus and Japanese encephalitis virus.

7. The use of any one of claims 1 to 6, wherein the medicament is formulated to be administered orally, sublingually, intravenously or intraperitoneally.